Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Short term Debt (2024 - 2025)

Historic Short term Debt for Viridian Therapeutics, Inc.\DE (VRDN) over the last 3 years, with Q2 2025 value amounting to $8.4 million.

  • Viridian Therapeutics, Inc.\DE's Short term Debt rose 18458.16% to $8.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $8.4 million, marking a year-over-year increase of 18458.16%. This contributed to the annual value of $1.0 million for FY2014, which is N/A changed from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Short term Debt stood at $8.4 million for Q2 2025, which was up 18458.16% from $3.0 million recorded in Q2 2024.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Short term Debt peaked at $8.4 million during Q2 2025, and registered a low of $3.0 million during Q2 2024.